Literature DB >> 9541419

Serial flow cytometric analysis of T-cell surface markers can be useful in differential diagnosis of renal allograft dysfunction.

A I Beik1, A G Morris, R M Higgins, F T Lam.   

Abstract

We examined changes in the circulating T-cell subsets and their activation to see if consistent changes occur following renal transplantation, during acute rejection episodes (ARE), cytomegalovirus (CMV) infection, and cyclosporine (CsA) nephrotoxicity. Serial blood samples were taken from 28 patients on standard triple immunosuppresion therapy. Using two-colour flow cytometric analysis, the percentages of CD3+, CD4+, and CD8+ T-cells were determined, and coexpression of CD25, HLA/DR, and CD45 isoforms used to define their activation status. During ARE and CMV infection, increased levels of circulating CD4+ CD25+, CD8+ HLA/DR+, CD4+ CD45RO+, CD8+ CD45RO+ were observed. The increased levels of CD45RO+ T-cells were associated with a significant decrease in the percentages of CD45RA+ of both CD4+ and CD8+ T-cells. No significant changes were seen during CsA nephrotoxicity. The pattern of marker expression seen during ARE and CMV infection was similar to that seen in Con-A stimulated T-lymphocytes from 22 normal controls. We conclude that, the increase in the levels of these surface markers do not differentiate between lymphocyte activation indicative of rejection or infection, but clearly distinguish episodes of CsA nephrotoxicity. These results could be useful in the differential diagnosis of renal allograft dysfunction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9541419

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  1 in total

1.  Down regulation of CD45 expression on CD4 T cells during acute renal allograft rejection: evidence of a decline in T suppressor/inducer activity.

Authors:  M Shabtai; W C Waltzer; A Ayalon; E L Shabtai; K Malinowski
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.